Kreuz_subbed.qxp 12/2/09 15:12 Page 20
Coagulation Disorders Haemophilia
1. Astermark J, Morado M, Rocino A, et al., Current European 26. van der Bom JG, Mauser-Bunschoten EP, Fischer K, et al., 1993;81:3332–5.
practice in immune tolerance induction therapy in patients Age at first treatment and immune tolerance to factor VIII in 45. Chalmers EA, Brown SA, Keeling D, et al., Early factor VIII
with haemophilia and inhibitors, Haemophilia, 2006;12: severe haemophilia, Thromb Haemost, 2003;89:475–9. exposure and subsequent inhibitor development in children
363–71. 27. Escuriola-Ettingshausen C, Linde R, Martinez-Saguer I, et al., with severe haemophilia A, Haemophilia, 2007;13:149–55.
2. Kreuz W, Escuriola-Ettingshausen, Martinez-Saguer I, et al., The role of therapy regimen and age at first exposure on 46. Gouw SC, van der Bom JG, Auerswald G, et al., Recombinant
Epidemiology of inhibitors in haemophilia A, Vox Sang, inhibitor development in patients with severe haemophilia A. versus plasma-derived factor VIII products and the
1996;70(Suppl.1):2–8. In: Scharrer I, Schramm W (eds), 34th Hemophilia Symposium development of inhibitors in previously untreated patients
3. Kreuz W, Ehrenforth S, Funk M, et al., Immune tolerance Hamburg 2003, Heidelberg: Springer Medizin Verlag, with severe hemophilia A: the CANAL cohort study, Blood,
therapy in paediatric haemophiliacs with factor VIII inhibitors: 2006;39–41. 2007;109:4693–7.
14 years follow-up, Haemophilia, 1995;1(1):24–32. 28. von Auer Ch, Oldenburg J, von Depka M, et al., Inhibitor 47. Auerswald G, Spranger T, Brackmann HH, The role of
4. DiMichele DM, Immune tolerance therapy for factor VIII development in patients with hemophilia A after continuous plasma-derived factor VIII/von Willebrand factor concentrates
inhibitors: moving from empiricism to an evidence-based infusion of FVIII concentrates, Ann NY Acad Sci, 2005;1051: in the treatment of hemophilia A patients, Haematologica/J
approach, J Thromb Haemost, 2007;5(Suppl.1):143–50. 498–505. Hematol, 2003;88(Suppl. 9):21–5.
5. Heimburger N, Schwinn H, Gratz P, et al., Factor VIII 29. Morado M, Villar A, Jiménez Yuste V, et al., Prophylactic 48. Dasgupta S, Repessé Y, Bayry J, et al., VWF protects FVIII
concentrate, highly purified and heated in solution, Arzneim- treatment effects on inhibitor risk: experience in one centre, from endocytosis by dendritic cells and subsequent
Forsch/Drug Res, 1981;31(I4):619–22. Haemophilia, 2005;11:79–83. presentation to immune effectors, Blood, 2007;109:610–12.
6. Kreuz W, Becker S, Auerswald G, et al., Virus safety of 30. Escuriola-Ettingshausen C, Kreuz W, Recombinant vs. 49. Behrmann M, Pasi J, Saint-Remy JMR, et al., Von Willebrand
pasteurized clotting factor concentrates, Semin Thromb plasma-derived products, especially those with intact VWF, factor modulates factor VIII immunogenicity: comparative
Hemost, 2002;28(Suppl. 1):57–61. regarding inhibitor development, Haemophilia, study of different factor VIII concentrates in a haemophilia A
7. Colombo M, Mannucci PM, Carnelli V, et al., Transmission of 2006;12(Suppl. 6):102–6. mouse model, Thromb Haemost, 2002;88:221–9.
non-A, non-B hepatitis by heat-treated factor VIII 31. Wight J, Paisley S, The epidemiology of inhibitors in 50. Lin Y, Yang X, Chevrier MC, et al., Relationship between
concentrate, Lancet, 1985;(II):1–4. haemophilia A: a systematic review, Haemophilia, 2003;9: factor VIII:Ag and factor VIII in recombinant and plasma-
8. Boedeker BGD, Production processes of licensed recombinant 418–35. derived factor VIII concentrates, Haemophilia,
factor VIII preparations, Semin Thromb Hemost, 2001;27(4): 32. Kreuz W, Gill JC, Rothschild C, et al., Full-length sucrose- 2004;10(5):459–69.
385–94. formulated recombinant factor VIII for treatment of previously 51. Escuriola-Ettingshausen C, Kreuz W, Role of von Willebrand
9. Berntorp E, Prophylaxis for haemophilia, Int J Pediatr Hematol untreated or minimally treated young children with severe factor in immune tolerance induction, Blood Coagul
Oncol, 1994;1:463–70. haemophilia A, Thromb Haemost, 2005;93:457–67. Fibrinolysis, 2005;16(Suppl. 1):S27–S31.
10. Brackmann HH, Eickhoff HJ, Oldenburg J, et Hammerstein U, 33. Oldenburg J, Ivaskevicius V, Schröder J, et al., Genetic 52. DiMichele DM, Immune tolerance: a synopsis of the
Long-term therapy and on-demand treatment of children and background and inhibitors in previously untreated or international experience, Haemophilia, 1998;4:568–73.
adolescents with severe haemophilia A: 12 years of minimally treated young patients with severe haemophilia A 53. Brackmann HH, Lenk H, Scharrer I, et al., German
experience, Haemostasis, 1992;22(5):251–8. treated with sucrose-formulated recombinant factor VIII, recommendations for immune tolerance therapy in
11. Aledort LM, Haschmeyer RH, Pettersson H, A longitudinal Thromb Haemost, 2006;95:903–5. type A haemophiliacs with antibodies, Haemophilia,
study of orthopaedic outcomes for severe factor-VIII-deficient 34. Goudemand J, Rothschild C, Demiguel V, et al., Influence of 1999;5:203–6.
haemophiliacs, J Int Med, 1994;236:391–9. the type of factor VIII concentrate on the incidence of favtor 54. Brackmann HH, Induced immunotolerance in factor
12. Kreuz W, Escuriola-Ettingshausen C, Funk M, et al., When VIII inhibitors in previously untreated patients with severe VIII inhibitor patients, Prog Clin Biol Res, 1984;150:
should prophylactic treatment in patients with haemophilia A hemophilia A, Blood, 2006;107:46–51. 181–95.
and B start? – The German experience, Haemophilia, 1998;4: 35. Courter SG, Bedrosian CL, Clinical evaluation of B-domain 55. van Leeuwen EF, Mauser-Bundschoten EP, van Dijken PJ,
413–17. deleted recombinant factor VIII in previously untreated et al., Disappearance of factor VIII:C antibodies in patients
13. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al., patients, Semin Hematol, 2001;38:52–9. with haemophilia A upon frequent administration of factor
Prophylaxis versus episodic treatment to prevent joint disease 36. Rothschild C, Laurian Y, Satre EP, et al., French previously VIII in intermediate or low dose, Br J Haematol, 1986;64:
in boys with severe hemophilia, N Engl J Med, 2007;357(6): untreated patients with severe haemophilia A after exposure 291–7.
535–44. to recombinant factor VIII: incidence of inhibitor and 56. Nilsson IM, Berntorp E, Zettervall O, Induction of immune
14. Ehrenforth S, Kreuz W, Scharrer I, et al., Incidence of evaluation of immune tolerance, Thromb Haemost, 1998;80: tolerance in patients with haemophilia and antibodies to
development of factor VIII and factor IX inhibitors in 779–83. factor VIII by combined treatment with intravenous IgG,
haemophiliacs, Lancet, 1992;339:594–8. 37. Bray GL, Gomperts ED, Courter SG, A multicenter study of cyclophosphamide and factor VIII, N Engl J Med, 1988;318:
15. Oldenburg J, Schröder J, Brackmann HH, et al., recombinant factor VIII (Recombinate): safety, efficacy, and 947–50.
Environmental and genetic factors influencing inhibitor inhibitor risk in previously untreated patients, Blood, 57. Ehrenforth S, Kreuz W, Funk M, et al., Variables that might
development, Semin Hematol, 2004;41(1 Suppl. 1):82–8. 1997;83:2428–35. affect the outcome of immune tolerance therapy in
16. Santagostino E, Mancuso ME, Rocino A, et al., Environmental 38. Lusher JM, Arkin S, Abildgaard CF, et al., Recombinant haemophiliacs with factor VIII inhibitors, Thromb Haemost,
risk factors for inhibitor development in children with factor VIII (Kogenate) for the treatment of previously 1994;72(5):782–6.
haemophilia A: a case-control study, Br J Haematol, untreated patients with haemophilia A. Safety, efficacy 58. Brackmann HH, Oldenburg J, Schwaab R, Immune tolerance
2005;130:422–7. and development of inhibitors, N Engl J Med, 1993;328: for the treatment of factor VIII inhibitors – Twenty years
17. Astermark J, Why do inhibitors develop? Principles of and 453–9. ‘Bonn protocol’, Vox Sang, 1996;70(Suppl. 1):30–35.
factors influencing the risk for inhibitor development in 39. Gringeri A, Monzini M, Tagariello G, et al., Occurrence of 59. Gringeri A, Mannucci PM, Italian guidelines for the diagnosis
haemophilia, Haemophilia, 2006;12(Suppl. 3):52–60. inhibitors in previously untreated or minimally treated and treatment of patients with haemophilia and inhibitors,
18. Gouw SC, van der Bom JG, van den Berg HM, Treatment- patients with haemophilia A after exposure to a plasma- Haemophilia, 2005;11:611–19.
related risk factors of inhibitor development in previously derived solvent-detergent factor VIII concentrate, 60. DiMichele DM, Hay CRM, The international immune tolerance
untreated patients with hemophilia A: the CANAL cohort Haemophilia, 2006;12:128–32. study: a multicenter prospectice randomized trial in progress,
study, Blood, 2007;109(11):4648–54. 40. Rokicka-Milewska R, Klukowska A, Dreger B, et al., Incidence J Thromb Haemost, 2006;4:2271–3.
19. Oldenburg J, Mutation profiling in haemophilia A, Thromb of FVIII inhibitor development in previously untreated 61. Kreuz W, Escuriola-Ettingshausen C, Auerswald G, et al.,
Haemost, 2001;85:577–9. haemophilia A patients after exposure to a double virus Immune tolerance induction (ITI) in haemophilia A patients
20. Schwaab R, Brackmann HH, Meyer C, Haemophilia A: inactivated factor VIII concentrate, Ann Haematol, with inhibitors – The choice of concentrate affecting success,
Mutation type determines risk of inhibitor formation, Thromb 1999;78(Suppl. 1):1–7. Haematologica/J Hematol, 2001;86(Suppl. 4):16–22.
Haemost, 1995;74:1402–6. 41. Yee TT, Williams MD, Hill FG, et al., Absence of inhibitors in 62. Berntorp E, Ekman M, Gunnarsson M, et al., Variation in
21. Aledort LM, DiMichele DM, Inhibitors occur more frequently previously untreated patients with severe haemophilia A after factor VIII inhibitor reactivity with different commercial factor
in African-American and Latino haemophiliacs, Haemophilia, exposure to a single intermediate purity factor VIII product, VIII preparations, Haemophilia, 1996;2:95–9.
1998;4:68. Thromb Haemost, 1997;78:1027–9. 63. Suzuki T, Arai M, Amano K, et al., Factor VIII inhibitor
22. Gill JC, The role of genetics in inhibitor formation, Thromb 42. Schimpf K, Schwarz P, Kunschak M, Zero incidence of antibodies with C2 domain specificity are less inhibitory to
Haemost, 1999;82:500–504. inhibitors in previously untreated patients who received factor VIII complexed with von Willebrand factor, Thromb
23. Astermark J, Berntorp E, White GC, et al., The Malmö intermediate purity factor VIII concentrate or factor IX Haemost, 1996;76:749–54.
International Brother Study (MIBS): further support for complex, Thromb Haemost, 1995;73:553–5. 64. Astermark J, Voorberg J, Lenk H, et al., Impact of the
genetic predisposition to inhibitor development in 43. Guerois C, Laurian Y, Rothschild C, et al., Incidence of inhibitor epitope profile on the neutralizing effect against
haemophilia patients, Haemophilia, 2001;7:267–72. factor VIII inhibitor development in severe haemophilia A plasma-derived and recombinant factor VIII concentrates in
24. Kreuz W, Escuriola-Ettingshausen C, Auerswald G, et al., patients treated only with one brand of highly-purified vitro, Haemophilia, 2003;9:567–72.
Epidemiology of inhibitors and current treatment strategies, plasma-derived concentrate, Thromb Haemost, 1995;73: 65. Schramm W, Consensus recommendations for the
Haematologica/J Hematol, 2003;88(Suppl. 9):17–20. 215–18. haemophilia treatment in Germany, Hämostaseologie,
25. Lorenzo JI, Lopez A, Altisent C, et al., Incidence of factor VIII 44. Peerlinck K, Rosendaal FR, Vermylen J, Incidence of inhibitor 1994;14:81–3.
inhibitors in severe haemophilia: the importance of patient development in a group of young haemophilia A patients
age, Br J Haematol, 2001;113:600–603. treated exclusively with lyophylized cryoprecipitate, Blood,
20 EUROPEAN HAEMATOLOGY
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100